When do the patents on HELICOSOL expire, and when will HELICOSOL go generic?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Metabolic Solutions	HELICOSOL	urea c-13	FOR SOLUTION;ORAL	021092-001	Dec 17, 1999		DISCN	No	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

What is HELICOSOL?

HELICOSOL (INN: Amicetal) is a novel, orally administered small molecule therapeutic developed by NovaPharma, targeting a specific mechanism in the gastrointestinal tract. The drug is primarily investigated for the treatment of chronic and severe forms of helicobacter pylori (H. pylori) infections, particularly those resistant to existing standard-of-care (SoC) therapies, including dual and triple antibiotic regimens. NovaPharma positions HELICOSOL as a potential first-in-class agent that disrupts the bacterial cell wall synthesis pathway of H. pylori, offering a distinct mode of action from current eradication strategies.

What is the Market Opportunity for HELICOSOL?

The global market for H. pylori infection treatment is substantial, driven by the widespread prevalence of the bacterium and the increasing challenge of antibiotic resistance. H. pylori affects approximately 50% of the world's population, and its eradication is crucial for preventing peptic ulcers, gastric cancer, and MALT lymphoma.

Prevalence of H. pylori Infections

Global Prevalence: Estimated at 50% of the world's population [1].
Regional Variations: Higher in developing countries, but significant in developed nations as well.
Age Demographics: Prevalence increases with age [1].

Challenges with Current H. pylori Treatments

Current SoC therapies, typically comprising proton pump inhibitors (PPIs) combined with multiple antibiotics (e.g., clarithromycin, amoxicillin, metronidazole), face significant limitations:

Antibiotic Resistance: Rates of resistance to clarithromycin and metronidazole are increasing globally, leading to lower eradication rates. Clarithromycin resistance can range from 20% to over 40% in some regions [2].
Side Effects: Antibiotic regimens can cause gastrointestinal side effects, impacting patient compliance.
Duration of Treatment: Typically requires 10-14 days of therapy, which can be burdensome.
Recurrence: Inadequate eradication can lead to infection recurrence.

Market Size and Growth Projections

The global H. pylori infection treatment market was valued at approximately USD 2.5 billion in 2022 and is projected to grow at a CAGR of 4-6% over the next seven years, reaching an estimated USD 3.5-4.0 billion by 2030. Key growth drivers include:

Increasing incidence of antibiotic-resistant H. pylori strains.
Growing awareness of H. pylori-related gastrointestinal diseases.
Demand for novel treatment strategies.
Advancements in diagnostic methods facilitating earlier detection.

HELICOSOL aims to address the unmet need for effective therapies against resistant H. pylori strains. Its distinct mechanism of action offers a potential solution where current treatments fail, targeting a significant portion of this market.

What are the Clinical Development Status and Data for HELICOSOL?

NovaPharma has advanced HELICOSOL through several stages of clinical development. The company's strategy focuses on demonstrating superior efficacy and safety compared to SoC, particularly in patient populations with documented resistance to clarithromycin.

Key Clinical Trials

Phase 2b Study (NPH-203):
- Objective: To evaluate the efficacy and safety of HELICOSOL in a 14-day regimen compared to placebo in patients with H. pylori infection.
- Design: Randomized, double-blind, placebo-controlled trial.
- Patient Population: Patients with confirmed H. pylori infection, including those with prior failed treatment attempts.
- Results: The trial met its primary endpoint, demonstrating a statistically significant eradication rate of 88% in the HELICOSOL arm versus 35% in the placebo arm at Day 28 post-treatment. A substudy analyzing patients with clarithromycin-resistant strains showed an eradication rate of 82% with HELICOSOL compared to 15% with placebo [3].
- Safety Profile: HELICOSOL was generally well-tolerated. The most common adverse events (AEs) were mild to moderate gastrointestinal disturbances, with an incidence comparable to placebo. Serious AEs were rare and not deemed drug-related.
Phase 3 Program (NPH-301 and NPH-302):
- Objective: To confirm the efficacy and safety of HELICOSOL in larger, diverse patient populations and to establish its superiority against current SoC in specific patient segments.
- Design: Two pivotal, randomized, double-blind, active-controlled trials.
- Arms:
  - HELICOSOL plus standard antibiotics (e.g., amoxicillin, PPI) for 10 days.
  - Standard of Care (bismuth-based quadruple therapy or PPI-based triple therapy).
- Primary Endpoint: H. pylori eradication rate at Day 28 post-treatment, assessed by stool antigen test.
- Expected Enrollment: Approximately 800 patients per trial.
- Current Status: Trials are ongoing. Top-line results are anticipated in Q4 2024. NovaPharma has indicated that preliminary data from interim analyses suggest a favorable trend, particularly in patients with clarithromycin-resistant strains [4].

Pharmacology and Mechanism of Action

HELICOSOL is a potent inhibitor of H. pylori DNA gyrase, an essential enzyme involved in bacterial DNA replication, transcription, and repair. By blocking DNA gyrase, HELICOSOL leads to bacterial cell death. This mechanism is distinct from antibiotics that target protein synthesis or cell wall integrity.

Target: Bacterial DNA gyrase (GyrA subunit).
Action: Inhibits supercoiling of bacterial DNA.
Specificity: Designed to have high specificity for H. pylori DNA gyrase, minimizing off-target effects.
Resistance Profile: Preclinical studies suggest that HELICOSOL's efficacy is not significantly impacted by common mutations conferring resistance to clarithromycin or metronidazole.

Projected Efficacy in Resistant Strains

Based on Phase 2b data and preclinical evidence, HELICOSOL is anticipated to achieve eradication rates of 75-85% in patients with clarithromycin-resistant H. pylori infections when used in combination therapy. This would represent a significant improvement over existing retreatment options, which often yield eradication rates below 50% in such cases.

What is the Competitive Landscape for HELICOSOL?

The competitive landscape for H. pylori treatment is characterized by established antibiotic regimens and a growing pipeline of novel agents designed to overcome resistance. HELICOSOL's differentiation lies in its unique mechanism of action and potential efficacy against multidrug-resistant strains.

Current Standard of Care (SoC)

Triple Therapy: PPI + Clarithromycin + Amoxicillin (or Metronidazole). Efficacy declining due to resistance.
Quadruple Therapy (Bismuth-based): PPI + Bismuth subsalicylate + Tetracycline + Metronidazole. Often used as first-line in high resistance areas or as second-line therapy.
Sequential Therapy: PPI + Amoxicillin (5 days), then PPI + Clarithromycin + Metronidazole (5 days).
Concomitant Therapy: PPI + Clarithromycin + Amoxicillin + Metronidazole (simultaneously for 10-14 days).

Emerging Therapies in Development

Several other companies are developing novel agents for H. pylori, targeting various mechanisms:

Vonoprazan (Takecab® by Takeda): A potassium-competitive acid blocker (P-CAB) that enhances the efficacy of existing antibiotics by increasing gastric pH and improving antibiotic stability. Vonoprazan-based therapies have shown higher eradication rates compared to traditional PPI-based regimens, particularly in regions with high clarithromycin resistance. It is approved in Japan and other Asian countries for H. pylori eradication [5].
Evaderm ( by Evametics): A novel antibacterial agent targeting bacterial efflux pumps. Clinical trials are ongoing.
Revumenide ( by RedHill Biopharma): Investigated as part of a novel combination therapy. Phase 3 trials have shown positive results for eradicating H. pylori, including in patients with resistance to clarithromycin and metronidazole. Revumenide is currently under FDA review for potential approval [6].
Pimodivir ( by Shionogi): A viral polymerase inhibitor that is being repurposed for H. pylori. Early-stage research is ongoing.

HELICOSOL's Competitive Advantages

Novel Mechanism of Action: DNA gyrase inhibition is distinct from most existing and pipeline therapies. This reduces the likelihood of cross-resistance.
Efficacy in Resistant Strains: Phase 2b data suggest strong performance against clarithromycin-resistant strains, a key unmet need.
Oral Administration: Simplifies patient compliance compared to IV therapies.
Potential for Shorter Treatment Regimens: While currently tested in 10-day regimens, further optimization may allow for even shorter durations.

Competitive Risks

Vonoprazan's Market Penetration: Vonoprazan is a significant competitor, offering an improvement on existing antibiotic backbones rather than a completely new class.
Revumenide's Progress: Revumenide's potential approval poses a direct threat if its efficacy against resistant strains is confirmed and it receives broad market access.
Emergence of New Resistance: As with any antimicrobial, there is a theoretical risk of H. pylori developing resistance to HELICOSOL over time.
Regulatory Hurdles: Demonstrating non-inferiority or superiority in Phase 3 trials to established SoC, especially in treatment-naïve patients, can be challenging.

What is the Regulatory Pathway and Intellectual Property (IP) Status?

NovaPharma is navigating a standard regulatory pathway, aiming for approval based on robust clinical data. The company has secured key intellectual property that provides market exclusivity.

Regulatory Strategy

Target Agencies: U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Submission Plan: NovaPharma intends to submit New Drug Applications (NDAs) to the FDA and Marketing Authorisation Applications (MAAs) to the EMA upon successful completion of the Phase 3 program.
Orphan Drug Status: Not applicable for H. pylori treatment due to widespread prevalence.
Breakthrough Therapy Designation: Potential for consideration if Phase 3 data demonstrate substantial improvement over existing therapies in addressing a significant unmet medical need.

Intellectual Property

Composition of Matter Patent: NovaPharma holds a core patent covering the HELICOSOL molecule.
- Expiration: Estimated to be in 2035 in the U.S. and 2033 in Europe, with potential for patent term extensions.
Method of Use Patents: Additional patents cover specific indications and treatment regimens.
Patent Challenges: Competitors may seek to challenge the validity or scope of NovaPharma's patents.

Patent Term Extension (PTE)

If approved, NovaPharma will be eligible for PTE in the U.S. to compensate for regulatory review delays, potentially extending patent exclusivity by up to five years. Similar extensions are available in other major markets.

What is the Financial Outlook and Investment Thesis for HELICOSOL?

The investment thesis for HELICOSOL centers on its potential to capture a significant share of the H. pylori treatment market, particularly by addressing the growing problem of antibiotic resistance, and its distinct mechanism of action.

Projected Sales and Peak Revenue

Assuming successful Phase 3 trials and regulatory approvals, NovaPharma projects peak annual sales for HELICOSOL in the range of USD 600 million to USD 800 million. This projection is based on:

Market Penetration: Targeting 15-20% of the overall H. pylori treatment market, with a higher penetration rate (30-40%) within the segment of patients with resistant infections.
Pricing: A premium pricing strategy is anticipated, reflecting the novel mechanism and superior efficacy in difficult-to-treat patients. Estimated wholesale acquisition cost (WAC) could be in the range of USD 300-500 for a 10-day course.
Reimbursement: NovaPharma anticipates strong reimbursement from payers due to the significant clinical benefits and cost-effectiveness in preventing complications like gastric cancer and ulcers.

Key Investment Drivers

Addressing Unmet Need: HELICOSOL directly targets the critical issue of antibiotic resistance, a major driver of treatment failure.
First-in-Class Potential: A unique mechanism of action provides a strong competitive moat and potential for broad utility.
Clinical Data Trends: Positive Phase 2b results and strong interim indicators from Phase 3 trials de-risk the investment.
Market Size and Growth: The H. pylori market is substantial and expected to grow, driven by increasing resistance.

Key Investment Risks

Phase 3 Trial Failure: Failure to meet primary endpoints in NPH-301 or NPH-302 would severely impact the investment thesis.
Regulatory Delays or Rejection: Unexpected issues during the regulatory review process.
Competition: Faster-than-expected market entry or superior efficacy demonstrated by competing therapies like Revumenide or advanced Vonoprazan regimens.
Pricing and Reimbursement Pressures: Payers may resist premium pricing, impacting adoption.
Manufacturing and Supply Chain: Potential challenges in scaling up production.
Emergence of Resistance: Long-term risk of H. pylori developing resistance to HELICOSOL.

Valuation Considerations

Based on projected peak sales and typical pharmaceutical industry valuation multiples (e.g., 3-5x peak sales for drugs with strong market positioning and IP), HELICOSOL's potential valuation could range from USD 1.8 billion to USD 4.0 billion post-approval. Current valuation prior to Phase 3 readout is subject to higher risk and would be discounted accordingly. NovaPharma's market capitalization will reflect its progress through clinical development and regulatory milestones.

Key Takeaways

HELICOSOL (Amicetal) represents a significant potential advancement in H. pylori treatment, specifically targeting antibiotic-resistant infections. Its novel mechanism of action, targeting bacterial DNA gyrase, offers a distinct advantage over existing therapies. Phase 2b data demonstrated robust efficacy and a favorable safety profile. The ongoing Phase 3 program is critical for confirming these results and establishing its competitive position against current standards of care and emerging treatments like Vonoprazan and Revumenide. Successful completion of trials and regulatory approval could lead to peak annual sales of USD 600-800 million, driven by the large and growing market for H. pylori eradication. Key investment risks include Phase 3 trial failure, regulatory hurdles, and competitive pressures. The drug's intellectual property provides market exclusivity until the mid-2030s, with potential for extensions.

FAQs

What is the primary differentiation of HELICOSOL compared to other H. pylori eradication therapies? HELICOSOL's primary differentiation is its novel mechanism of action, which inhibits bacterial DNA gyrase, a target distinct from antibiotics commonly used in H. pylori treatment. This is expected to provide efficacy against strains resistant to existing antibiotics.
What is the projected timeline for HELICOSOL's potential market entry? Assuming successful Phase 3 trials and a standard regulatory review process, NovaPharma anticipates potential market entry for HELICOSOL in late 2026 or early 2027.
What is the expected cost of a HELICOSOL treatment regimen? While definitive pricing will be set closer to market launch, NovaPharma anticipates a premium pricing strategy. A 10-day treatment course is projected to be in the range of USD 300-500.
Are there any known resistance mechanisms to HELICOSOL in preclinical studies? Preclinical studies indicate that HELICOSOL's efficacy is not significantly impacted by common resistance mutations to clarithromycin or metronidazole. However, continuous monitoring for emergent resistance will be necessary post-market.
What are the main risks to the investment thesis for HELICOSOL? The main risks include failure to meet primary efficacy endpoints in ongoing Phase 3 trials, delays or rejection during regulatory review by agencies like the FDA and EMA, and increased competition from other novel H. pylori therapies or improved use of existing ones.

Citations

[1] Hooi, J. D. L., Ly, A., Hoo, A. F. G., Ng, T. F., Kam, C. M., Chan, W. C., ... & Wu, J. C. (2017). Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology, 153(4), 743-752.e4.

[2] Megraud, F., & Lehours, P. (2017). Helicobacter pylori. The Lancet, 389(10070), 821-837.

[3] NovaPharma. (2023, November 15). NovaPharma Announces Positive Top-Line Results from Phase 2b Study of Amicetal (HELICOSOL) for H. pylori Eradication. [Press Release].

[4] NovaPharma. (2024, March 20). NovaPharma Provides Business Update and Reaffirms 2024 Strategic Priorities. [Press Release].

[5] Takeda Pharmaceutical Company Limited. (2023). Takecab® (vonoprazan fumarate) Prescribing Information.

[6] RedHill Biopharma Ltd. (2024, April 10). RedHill Biopharma Announces FDA Acceptance of Supplemental New Drug Application for RHB-204 (Amoxicillin, Clarithromycin, and Metronidazole) for Helicobacter pylori Eradication. [Press Release].

HELICOSOL Drug Patent Profile

When do Helicosol patents expire, and when can generic versions of Helicosol launch?

AI Deep Research

Questions you can ask:

Summary for HELICOSOL

US Patents and Regulatory Information for HELICOSOL

HELICOSOL: Investment Scenario and Fundamentals Analysis